Dermata Therapeutics Inc. Common Stock (DRMA)
Stock · NASDAQ · Health Care
$0.8449as of 10/16/2026
Price chart
Active signals
DRMA Signal Track Record
How signals performed across all stocks →What DRMA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 22 | -8.2% | 36% | October 8, 2026 |
| Volume Spike | 22 | -10.7% | 23% | September 24, 2026 |
| Bollinger Band Breakout | 12 | -18.3% | 8% | August 13, 2026 |
| Any 20-session window (baseline) | -9.2% | 28% |
Computed by MarketWall from daily closing prices since May 27, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About DRMA
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquar…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 9
- Website
- www.dermatarx.com/
Fundamentals
- 1-day range
- $0.7678$1.18
- Market cap
- $4.46M
- P/E (trailing)
- —
- P/E (forward)
- -0.24
- EPS (trailing)
- $-4.51
- Dividend yield
- —
- Beta
- 0.58
- Avg. volume
- 710.2K
Forecasts
1 analyst ratings
Dermata Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- DRMADermata Therapeutics Inc. Common Stock$0.86▼ 5.49%Market cap $4.46MP/E —$0.6032$4.66
- RNAZTransCode Therapeutics Inc. Common Stock$1.7▼ 5.56%Market cap $4.52MP/E —$1.52$15.94
- REVBRevelation Biosciences Inc. Common Stock$0.485▼ 36.35%Market cap $4.38MP/E 0.04$0.71$5.8
- ELABPMGC Holdings Inc. Common Stock$2.77▼ 8.88%Market cap $4.34MP/E —$2.59$2,671
- JAGXJaguar Health Inc. Common Stock$3.53▼ 23.20%Market cap $4.61MP/E —$2.35$1,268
- JUNSJupiter Neurosciences Inc. Common Stock$2.9▼ 7.48%Market cap $4.24MP/E —$2.25$135.75
- PPCBPropanc Biopharma Inc. Common Stock$0.342▲ 0.15%Market cap $4.76MP/E —$0.365$47.5
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| DRMA Dermata Therapeutics Inc. Common Stock | $4.46M | — | $0.86 | ▼ 5.49% | $0.6032$4.66 |
| RNAZ TransCode Therapeutics Inc. Common Stock | $4.52M | — | $1.7 | ▼ 5.56% | $1.52$15.94 |
| REVB Revelation Biosciences Inc. Common Stock | $4.38M | 0.04 | $0.485 | ▼ 36.35% | $0.71$5.8 |
| ELAB PMGC Holdings Inc. Common Stock | $4.34M | — | $2.77 | ▼ 8.88% | $2.59$2,671 |
| JAGX Jaguar Health Inc. Common Stock | $4.61M | — | $3.53 | ▼ 23.20% | $2.35$1,268 |
| JUNS Jupiter Neurosciences Inc. Common Stock | $4.24M | — | $2.9 | ▼ 7.48% | $2.25$135.75 |
| PPCB Propanc Biopharma Inc. Common Stock | $4.76M | — | $0.342 | ▲ 0.15% | $0.365$47.5 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Why Is Dermata Therapeutics Stock Gaining Thursday?benzinga · 10/15/2026
Insider Activity
Insider Actions →- Gerald T. Proehl · August 16, 2026 · Grant1.36M
- Gerald T. Proehl · August 16, 2026 · Grant170.1K
- Van Hoose Kyri K. · August 16, 2026 · Grant102.0K
- Kathleen D. Scott · June 16, 2026 · Sale11 @ $1.19
Institutional Ownership
March 31, 2026
- Total shares held
- 106.5K
- Total value held
- $128.9K
- Institutional holders
- 7
- Unknown48.3K
- Unknown35.6K
- Unknown20.0K
- Unknown1.7K
- Unknown716
- Unknown101
- Unknown1
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Dermata Reports Positive Results from Tome Cosmetic Study
Dermata Therapeutics said its Tome Foundational Treatment showed positive topline results in a cosmetic study. The study reported that more than 71% of patients had overall skin improvements at day 29. The company’s shares were active with a volume spike during the session. The stock sits near its 52‑week low and an RSI of 34.5.
Dermata Reports Positive Results from Tome Cosmetic Study. Dermata Therapeutics said its Tome Foundational Treatment showed positive topline results in a cosmetic study. The study reported that more than 71% of patients had overall skin improvements at day 29. The company’s shares were active with a volume spike during the session. The stock sits near its 52‑week low and an RSI of 34.5.